Botulinum neurotoxin treatment in children with cerebral palsy: validation of a needle placement protocol using passive muscle stretching and relaxing

Dev Med Child Neurol. 2016 Dec;58(12):1281-1287. doi: 10.1111/dmcn.13176. Epub 2016 Jul 6.

Abstract

Aim: To validate a detailed intramuscular needle placement protocol using passive muscle stretching and relaxing for botulinum neurotoxin type A (BoNT-A) treatment in the lower extremity of children with spastic cerebral palsy (CP), with verification by electrical stimulation.

Method: A prospective observational study was performed in 75 children with spastic CP who received regular BoNT-A treatment under general anaesthesia (52 males, 23 females; mean age 8y 9mo, SD 3y 7mo, range 4-18y; mean body mass index 16.2, SD 3.7, range 7.7-26.7). A total of 1084 intramuscular needle placements using passive muscle stretching and relaxing were verified by electrical stimulation. Primary outcome was the positive predictive value.

Results: Intramuscular needle placement in the muscles adductor brevis, adductor longus, gracilis, semimembranosus, semitendinosus, biceps femoris, rectus femoris, and lateral and medial heads of the gastrocnemius and soleus had a positive predictive value ranging from 85.7% to 100% (95% confidence interval ranging from 71.5-89.9% to 91.4-100%).

Interpretation: This validated detailed protocol for intramuscular needle placement using passive muscle stretching and relaxing for BoNT-A treatment in the lower extremity of children with spastic CP is reliable and has a high positive predictive value.

Publication types

  • Observational Study
  • Validation Study

MeSH terms

  • Adolescent
  • Botulinum Toxins, Type A / administration & dosage*
  • Cerebral Palsy / drug therapy*
  • Child
  • Child, Preschool
  • Clinical Protocols / standards*
  • Electric Stimulation
  • Female
  • Humans
  • Injections / methods*
  • Injections / standards
  • Injections, Intramuscular / methods
  • Male
  • Muscle, Skeletal*
  • Neuromuscular Agents / administration & dosage*

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A